PURPOSE: To evaluate whether core length impacts biopsy accuracy and Gleason score underestimation compared to radical prostatectomy (RP) specimens. METHODS: From 2010 to 2011, 8,928 cores were trans-rectal obtained from 744 consecutive patients (178 RP, 24%), 557 by an experienced performer (>250/year) and 187 (25%) by in-training urology residents. Prospectively analyzed variables were core length, age, prostate volume, free and total prostate-specific antigen (PSA), PSA density and free/total PSA ratio. RESULTS: Mean core length for Gleason upgrading on RP (42.7%, n = 76) was 11.61 (±2.5, median 11.40) compared to 13.52 (±3.2, median 13.70), p < 0.001 for perfect biopsy-RP Gleason agreement (57.3%, n = 102). In multivariate analysis, for each unit of core length increment in millimeter, the Gleason upgrading risk decreased 89.9%, p = 0.049 [odds ratio (OR) 0.10, 95% confidence interval (CI) 0.01-0.99]. Biopsy positivity between experienced (35.5%) and in-training performer (30.1%) was not significantly different (p = 0.20), with comparable mean patient age (65.1 vs. 64.1), prostate volume (52.3 vs. 50.7) and median PSA (5.2 vs. 5.1), respectively. Denoting wider variability in terms of core length, in-training performers obtained significantly larger cores for positive biopsies (11.33 ± 3.42 vs. 10.83 ± 3.68), p = 0.043, compared to experienced performer (11.39 ± 3.36 vs. 11.37 ± 3.64), p = 0.30. In multivariate analysis, PSA density (OR 1.14, 95% CI 1.02-1.28) and age (OR 1.04, 95% CI 1.01-1.07) were significantly associated with biopsy positivity, p = 0.021 and p = 0.011, respectively. CONCLUSION: While core length on trans-rectal biopsy independently affects Gleason upgrading on RP specimens, performer experience has minor impact on Gleason discordance or biopsy positivity due to a sharp learning curve.
PURPOSE: To evaluate whether core length impacts biopsy accuracy and Gleason score underestimation compared to radical prostatectomy (RP) specimens. METHODS: From 2010 to 2011, 8,928 cores were trans-rectal obtained from 744 consecutive patients (178 RP, 24%), 557 by an experienced performer (>250/year) and 187 (25%) by in-training urology residents. Prospectively analyzed variables were core length, age, prostate volume, free and total prostate-specific antigen (PSA), PSA density and free/total PSA ratio. RESULTS: Mean core length for Gleason upgrading on RP (42.7%, n = 76) was 11.61 (±2.5, median 11.40) compared to 13.52 (±3.2, median 13.70), p < 0.001 for perfect biopsy-RP Gleason agreement (57.3%, n = 102). In multivariate analysis, for each unit of core length increment in millimeter, the Gleason upgrading risk decreased 89.9%, p = 0.049 [odds ratio (OR) 0.10, 95% confidence interval (CI) 0.01-0.99]. Biopsy positivity between experienced (35.5%) and in-training performer (30.1%) was not significantly different (p = 0.20), with comparable mean patient age (65.1 vs. 64.1), prostate volume (52.3 vs. 50.7) and median PSA (5.2 vs. 5.1), respectively. Denoting wider variability in terms of core length, in-training performers obtained significantly larger cores for positive biopsies (11.33 ± 3.42 vs. 10.83 ± 3.68), p = 0.043, compared to experienced performer (11.39 ± 3.36 vs. 11.37 ± 3.64), p = 0.30. In multivariate analysis, PSA density (OR 1.14, 95% CI 1.02-1.28) and age (OR 1.04, 95% CI 1.01-1.07) were significantly associated with biopsy positivity, p = 0.021 and p = 0.011, respectively. CONCLUSION: While core length on trans-rectal biopsy independently affects Gleason upgrading on RP specimens, performer experience has minor impact on Gleason discordance or biopsy positivity due to a sharp learning curve.
Authors: David G Bostwick; Junqi Qian; Krystyna Drewnowska; Stephen Varvel; Kathleen C Bostwick; Michael Marberger; Roger S Rittmaster Journal: Urology Date: 2009-11-25 Impact factor: 2.649
Authors: D Colleselli; A E Pelzer; E Steiner; S Ongarello; G Schaefer; G Bartsch; C Schwentner Journal: Prostate Cancer Prostatic Dis Date: 2009-12-22 Impact factor: 5.554
Authors: Kenneth A Iczkowski; George Casella; R John Seppala; Galin L Jones; Barbara A Mishler; Junqi Qian; David G Bostwick Journal: Urology Date: 2002-05 Impact factor: 2.649
Authors: Nathan Lawrentschuk; Ants Toi; Gina A Lockwood; Andrew Evans; Antonio Finelli; Martin O'Malley; Myles Margolis; Sangeet Ghai; Neil E Fleshner Journal: J Urol Date: 2009-12 Impact factor: 7.450
Authors: Luigi Cormio; Vincenzo Scattoni; Fabrizio Lorusso; Antonia Perrone; Giuseppe Di Fino; Oscar Selvaggio; Francesca Sanguedolce; Pantaleo Bufo; Francesco Montorsi; Giuseppe Carrieri Journal: World J Urol Date: 2012-11-25 Impact factor: 4.226
Authors: A Pichon; Y Neuzillet; H Botto; J-P Raynaud; C Radulescu; V Molinié; J-M Herve; T Lebret Journal: Prostate Cancer Prostatic Dis Date: 2015-10-06 Impact factor: 5.554
Authors: Brunno C F Sanches; Ana Luiza Lalli; Wilmar Azal Neto; Athanase Billis; Leonardo Oliveira Reis Journal: World J Urol Date: 2018-03-01 Impact factor: 4.226
Authors: Walker W Laranja; Brunno C F Sanches; Brunno R I Voris; João C C Alonso; Fabiano A Simões; Ronald F Rejowski; Leonardo O Reis Journal: Prostate Cancer Date: 2019-04-01